Aim: The aim of the study was to evaluate the efficacy of gabapentin (1600 mg/d) as an adjunctive to methadone-assisted detoxification in the treatment of opioid withdrawal symptoms.
A ddiction is a worldwide epidemic that causes physical and psychosocial health problems and requires high costs for treatment. Despite an increased amount of treatment for the vast majority of complications, the relapse rate is still high. Once the addict stops taking drugs, acute withdrawal symptoms begin including back and leg pain, sleep disturbances, chronic fatigue, restlessness, and mood disorders. If left uncontrolled, these symptoms often result in treatment failure, relapse, and lethality without medical interventions. Therefore, controlling withdrawal symptoms is the first and very important step in any detoxification and rehabilitation program for patients addicted to opiate. 1 Strategies found to be effective for the treatment of opioid dependency include switching to methadone or buprenorphine followed by gradual tapering and use of nonopioid drugs at the final stages of methadone or buprenorphine tapering and transition to perhaps nonopiate maintenance methods such as naltrexone. Clonidine has for some time become the main nonopiate alternative for withdrawal treatment. However, it is not effective in the alleviation of muscle aches, insomnia, or drug craving. Moreover, it is associated with high rates of adverse effects such as sedation and hypotension that limit its use in outpatient setting. Lofexidine, in some countries, has replaced clonidine because of its fewer adverse effects. However, this drug is still not available in many countries. 1 The limited number of pharmacological options available for the maintenance treatment of opioid dependency led to an increasing interest in alternative pharmacological strategies.
Anticonvulsant drugs have been evaluated for the treatment of substance-abuse patients because of their lack of addiction potential and their efficacy in comorbid psychiatric disorders and pain conditions. 2 The role of kindling mechanisms in withdrawal syndromes is another rationale for using antiepileptic drugs in this case. 3 Preliminarily evidence is available on the efficacy of carbamazepine, valproate, lamotrigine, and gabapentin for detoxification from benzodiazepines, alcohol, and opiates, yet to be confirmed by further well-designed controlled trials. 3 In the first phase of this study, a dose of 900 mg/d of gabapentin for 3 weeks was not significantly superior to placebo in controlling opiate withdrawal symptoms. 4 However, according to its clinical effects in reducing some particular symptoms such as dysphoria, muscle spasm and twitching, irritability, and craving for the substance, we conducted the second phase of this study to evaluate the efficacy of a higher dose of gabapentin (1600 mg/d) as an adjunctive in methadone-assisted detoxification (MAD).
METHODS

Recruitment and Setting
This study was conducted at an outpatient clinic for addictive behaviors in the Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Opioiddependent outpatients were invited to participate in the study. The criteria for inclusion were opioid dependency, based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, for at least 1 year and stable dose of opium for at least 1 month before the study. The exclusion criteria were having a history of illicit drug use other than opium and/or psychiatric medication or other substances except cigarettes for a period of 2 months before the study. Patients with major psychiatric disorder, severe concurrent medical illness, organic brain disorder, and mental retardation and also pregnant or lactating women were excluded from the study. The ethics committee of Isfahan University of Medical Sciences approved the study, and informed consent was obtained from all patients after a full explanation of the study protocol.
Study Design and Medication
This study was an open-label clinical trial of add-on gabapentin to MAD (as second phase) following a double-blind, placebo-controlled study (as first phase) 4 of a series of studies for evaluation of the role of gabapentin in controlling opioid withdrawal symptoms with the same methodology (including blindness of raters on the dose of gabapentin and omission of placebo) except for higher dose of gabapentin and larger sample size as the third group of the first phase. Subjects were selected randomly among outpatients referred to our clinic and received gabapentin in addition to MAD for about 3 weeks. The dose of gabapentin was increased from 800 mg/d on the first day to 1600 mg/d at day 3, in increments of 400 mg/d. This dose was maintained until the end of the trial. All patients received MAD using a 3-week course of methadone and symptomatic medication (ie, clonidine, oxazepam, or trazodone) if required. Methadone was prescribed at a dose of 20 to 65 mg/d, based on the amount of opium used in the last month before entering the study. Moreover, the dose of methadone was adjusted based on withdrawal symptoms and signs after cessation of opium for the first 3 days. It was reduced by 7.5% of initial dose per day during the following 14 days. Probable use of illicit drugs during the study was monitored by interview and also by urine test in doubtful cases. Exclusion from the study did not interfere with standard treatment. Compliance of the patients for using gabapentin was checked by interviewing in each symptom evaluation point (see below), and patients were encouraged to adhere to the treatment program.
Assessments and Data Analysis
The Subjective Opiate Withdrawal Scale (SOWS), a valid and reliable indicator of the severity of the opiate withdrawal syndrome, was administered at 6 points during the study: day 0 (baseline or early initiation of withdrawal symptoms) and end of days 3 (initiation of methadone tapering), 7, 10, 14, and 18 (end point of methadone therapy). This scale contains 16 symptoms, and the intensity of each symptom is rated from 0 (not at all) to 4 (extremely), so the total score is between 0 and 64.
All participants were asked to disclose their probable noncompliance or partial compliance with prescribed orders and use of other illicit drugs in each time of ratings.
Data were analyzed using SPSS version 15.0 (SPSS Inc, Chicago, Ill). Repeated-measures analysis of variance (ANOVA) was used to detect changes through the trial, controlling for age of participants and dose of methadone used. Data of this phase of study were also compared with those of the first phase of the trial with gabapentin 900 mg/d. 4 For this purpose, baseline characteristics and total SOWS scores at each measurement point were compared between the groups by ANOVA. The KruskalWallis test was used to compare the total score of each symptom between the groups.
RESULTS
During the study period (July to December 2008), 31 opioid-dependent outpatients (29 males) with a mean age of 32.38 (SD, 9.5) years (range, 19Y55 years) were included. Twenty-seven patients completed the trial, and 4 patients were excluded because of relapse to opiate use (based on urine toxicology) because of intolerability to withdrawal symptoms (as patients reported in interview with them). All other patients reported that they consume gabapentin regularly in a genuine interview The most frequently reported adverse effects were dizziness and sedation, but in none of the patients it resulted in discontinuation of the drug or need to reduce the dose.
Total SOWS scores are presented in Table 1 along with data of the first phase of the study for comparison.
The 3 groups (gabapentin 900 and 1600 mg/d and placebo) were similar (no significant differences) in baseline characteristics: age, baseline severity of symptoms, and mean dose of methadone and other drugs used for symptomatic treatment during intervention. Repeated-measures ANOVA showed no significant change in total SOWS scores from baseline to the end of the intervention (F 5,52 = 0.69, P = 0.62). Gabapentin 1600 mg/d was significantly superior to gabapentin 900 mg/d and placebo in decreasing total baseline SOWS scores with 94% confidence (F 2,56 = 2.94, P = 0.06) ( Table 2) .
Gabapentin 1600 mg/d was significantly superior to gabapentin 900 mg/d and placebo in decreasing total scores of feeling of coldness (P = 0.016), yawing (P = 0.06), diarrhea (P = 0.06), dysphoria (P = 0.042), and muscle tension (P = 0.01) ( Table 3) .
DISCUSSION
Considering the limited number of pharmacological options available for the treatment of opioid dependency, there is an increasing interest in alternative pharmacological strategies. In this regard, anticonvulsants and agonists of F-aminobutyric acid (GABA) such as carbamazepine, topiramate, tiagabine, gabapentin, and baclofen have been studied with some promise. 3 Gabapentin is approved by the Food and Drug Administration as an adjunctive agent for the treatment of partial seizures. Along with anticonvulsant effects, it is effective in neuropathic as well as other chronic pain conditions. 5 It is also reported as a useful pharmacological agent for several psychiatric and behavioral disorders. This medication is a cyclic analog of GABA that stimulates and increases GABA release 6 and synthesis 7 in the brain. Although the mechanism of action is not completely understood, it seems to act by inhibition of the neuronal Ca 2+ channel. Although opiate withdrawal syndrome is hypothesized to be due to postYinhibitory excitatory syndrome, 8 gabapentin enhances GABAergic activity or modulates the release of excitatory neurotransmitters. 9 Data are available on the potential efficacy of gabapentin in the treatment of substance use disorders such as cocaine, 10, 11 heroin, 12 and alcohol 13, 14 dependence and withdrawal, although further controlled trials with larger sample sizes did not confirm the results of these case studies. 15, 16 In an open-label study comparing trazodone and gabapentin for the treatment of insomnia in alcohol-dependent individuals, both medications were found to improve insomnia, but the gabapentin group showed greater improvements than did the trazodone group. 17 Freye et al 18 reported that gabapentin acted as an effective antihyperalgesic agent for relieving opioid withdrawal hyperalgesia and restlessness in patients undergoing rapid opiate detoxification. Hyperactivity of noradrenergic neurons within the locus ceruleus has been proposed to play a critical role in the physiological and behavioral responses that comprise opioid withdrawal. 19 Furthermore, much recent interest has been focused on the putative involvement of glutamate within the locus ceruleus, as one member of the excitatory amino acid neurotransmitter family, in the development of dependence on opioids, because several results obtained from a variety of molecular biological, electrophysiological, biochemical, and behavioral studies indicate that glutamate and its receptors participate in both the withdrawal-associated increase in neuronal activity of locus ceruleus and the expression of opioid withdrawal behaviors. 20 Gabapentin selectively inhibits voltage-gated Ca 2+ channels and entails an increase in GABA neurotransmission, as well as a modulation of excitatory amino acids at the N-methyl-Daspartate receptor sites, 21, 22 which are increased in the withdrawal period. This assumption is underlined by the successful use of gabapentin in a number of chronic, naturopathic pain disorders. 23, 24 This makes this agent a useful candidate to alleviate hyperexcitatory painful states, as those observed in opiate withdrawal. 
